Utility and Limitations of SARS-CoV-2 Serology Testing

Get in Touch

Our Locations

Patrice Hugo, Ph.D.

Utility and Limitations of SARS-CoV-2 Serology Testing

AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention

In this presentation, you will learn why:

Highly sensitive and specific serological tests might not be the answer
Serological test results are not actionable in the absence of biological context
Disease prevalence and test positioning are key parameters to consider

Related Thought Leaders Insights

Scientific Poster

Robust performance of single-cell multiomic analysis (CITE-Seq) demonstrated across multiple locations, replicates, and donors on challenging cryopreserved PBMC and BMMC samples

Q² Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-Seq with BioLegend. Describes CITE-Seq performance expectations for...

Brochure

Challenging Bioanalytical Work

If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...

Factsheet

CNS Biomarkers

Rules-Based Medicine, a Q² Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...